|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Watson Pharmaceuticals Inc.: PharmaVitae Model
|
Jan 2009 |
£3,605 |
100% |
|
IMS Company Profiles: Watson
|
Jan 2012 |
£640 |
99% |
|
Watson Pharmaceuticals Generics Company Intelligence Report
|
Jan 2011 |
£195 |
99% |
|
Watson Pharmaceuticals: Corporate Analysis
|
May 2008 |
£255 |
99% |
|
Watson Pharmaceuticals Inc-Therapeutic Competitors
|
Mar 2011 |
£220 |
99% |
|
Watson Pharmaceuticals Inc-Detailed Product Pipeline
|
Mar 2011 |
£475 |
99% |
Watson
Pharmavitae Generics Profile
|
Sep 2007 |
£2,400 |
99% |
Watson Pharmaceuticals - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
98% |
|
Watson Pharmaceuticals Inc-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
|
Partnering Agreements with Watson 2010
|
Jan 2010 |
£630 |
97% |
Generics Market Outlook
2015
|
Oct 2010 |
£4,805 |
87% |
The World Generic Market Report
2011
|
Feb 2011 |
£795 |
86% |
|
Emerging Opportunities in Controlled-Release Generic Drugs
|
Aug 2009 |
£995 |
83% |
Laboratory Pumping Systems
Global Market Opportunities
|
Nov 2009 |
£1,895 |
82% |
Generic Drugs: World Market Outlook
22011-2021
|
Sep 2011 |
£1,699 |
82% |
Global Intravenous (IV) Iron Drugs Market
2011 Edition
|
Jan 2012 |
£505 |
80% |
Generic Growth Strategies
Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
|
May 2011 |
£2,215 |
79% |
HRA Pharma, SA – Product Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
78% |
|
Laboratory Pumping Systems
|
Oct 2008 |
£2,500 |
77% |
|
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2010
|
Mar 2010 |
£995 |
76% |
|
Narcolepsy Therapeutics
|
Jul 2010 |
£2,180 |
76% |
Greece Pharmaceuticals and Healthcare Report Q3
2011
|
Jul 2011 |
£330 |
76% |
Cardiovascular Generic Drugs
Prospects and Opportunities to 2012
|
Dec 2007 |
£995 |
76% |
Paladin Labs Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
75% |
Partnering Agreements with Bigpharma
3rd Edition
|
Oct 2010 |
£630 |
74% |
|
Hormone Replacement Therapy (HRT)
|
Sep 2011 |
£2,655 |
74% |
|
Contraceptives
|
Oct 2010 |
£2,845 |
74% |
|
Women's Reproductive Disorders Therapeutics 2008-2018
|
Sep 2008 |
£1,499 |
74% |
|
Overactive Bladder (OAB) Therapeutics
|
Aug 2011 |
£2,845 |
74% |
Warner Chilcott Plc – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
74% |
